Share This

Found something you'd like to share with a colleague or friend? Fill out the form below to share it.


*Denotes Required Field
*Your name: *Your email:

*Friend's name: *Friend's email:
Optional Message:

This site contains information for licensed healthcare professionals in the United States. By entering this website you acknowledge that you are a licensed healthcare professional in the United States.

OKCANCEL

You are now leaving DigiFab.us

This link is provided as a service to our website visitors, and any information provided on this site is not specific to the use of DigiFab®.

Click "Yes" to proceed to or "No" to return to DigiFab.us.

YESNO

Digoxin toxicity can be difficult to recognize

Signs and symptoms of life-threatening or potentially life-threatening digoxin (also known as digitalis) toxicity include, but are not limited to, severe ventricular arrhythmias (including ventricular tachycardia or fibrillation), progressive bradycardia, second- or third-degree heart block not responsive to atropine, serum potassium levels exceeding 5.5 mEq/L in adults or 6 mEq/L in children with rapidly progressive signs and symptoms of digoxin toxicity, and neurologic symptoms (eg, visual disturbances, disorientation, and confusion).1,2

Digoxin is indicated to treat patients with mild to moderate heart failure

An estimated 5.8 million individuals living in the United States have heart failure, with 670,000 new cases occurring each year.3

Who's at risk for digoxin toxicity?

Risk factors for digoxin toxicity include advanced age (>80 years); a decrease in renal clearance or loss of renal function due to chronic disease, hypokalemia, hypomagnesemia, and hypothyroidism; and use of multiple concomitant prescription drugs like macrolide antibiotics or drugs that impair renal function or cause hypokalemia.2,4

Life-threatening digoxin toxicity can be difficult to recognize

DigiFab® Digoxin Immune Fab (Ovine) is a treatment for patients with life-threatening or potentially life-threatening digoxin toxicity or overdose and is clinically proven to effectively clear digoxin from the body. Digoxin toxicity can be difficult to recognize in patients whose health may already be compromised.

Since the signs and symptoms are non-specific, knowing what to look for is important in order to effectively treat digoxin toxicity.

Read about digoxin toxicity »

Digifab - MOA Video

Watch a video on the diagnosis and treatment of digoxin toxicity.

Watch Video
Digifab - Download Video

It is estimated that 5.8 million individuals in the US have chronic heart failure3

To report an adverse event or for 24-hour medical information, call 1-877-377-3784.

References
  1. DigiFab® [prescribing information]. BTG International Inc. January 2012.
  2. Schreiber D. Toxicity, digitalis. eMedicine from WebMD Web site. http://emedicine.medscape.com/article/814404-print. Updated December 2, 2009. Accessed June 11, 2010.
  3. Lloyd-Jones D, Adams RJ, Brown TM, et al. Executive summary: heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation. 2010;121(7):948-954.
  4. Wofford JL, Ettinger WH. Risk factors and manifestations of digoxin toxicity in the elderly. Am J Emerg Med. 1991;9(suppl 1):11-15.

Indication
DigiFab® Digoxin Immune Fab (Ovine) is indicated for the treatment of patients with life-threatening or potentially life-threatening digoxin toxicity or overdose. DigiFab® is not indicated for milder cases of digitalis toxicity.

Important Safety Information
Patients with poor cardiac function may deteriorate secondary to the withdrawal of the inotropic action of digoxin by DigiFab®.  Rapid drop in serum potassium concentration may occur after treatment with DigiFab®. Patients with known allergies to sheep protein, papaya, or papain are at higher risk of an anaphylactic reaction. Suicidal ingestion may involve more than one drug. Toxic effects of other drugs or poisons should not be overlooked. The most common adverse reactions (>7%) related to DigiFab® are worsening congestive heart failure (13%), hypokalemia (13%) and worsening atrial fibrillation (7%). Please see full prescribing information, including events, precautions, or warnings.